



GNI Group Ltd. Ranks 289th on Deloitte Technology Fast 500 Asia Pacific 2017, A Ranking Program of Fastest-Growing Technology Companies

December, 12 2017 - GNI Group Ltd., (TSE Mothers listed code: 2160) a leading life science company in Japan, announced today that it ranked 289th on the Deloitte Technology Fast 500 Asia Pacific 2017, with revenue growth of 175.31% based on the past three accounting periods.

Technology Fast500 Asia Pacific, announced annually by Deloitte Touche Tohmatsu Limited (DTTL), is a ranking of the 500 fastest-growing companies in the technology, media, and telecommunications (TMT) industries based on their revenue (sales) growth percentage for the last three accounting periods.

Please visit : www.deloitte.com/fast500asiapacific

The Deloitte Technology Fast500 is the pre-eminent technology awards program in Asia Pacific, and now in its 16th year includes eight Asia Pacific locations: Australia; China (including Hong Kong); India; Japan; South Korea; New Zealand; Singapore and Taiwan. Combining technological innovation, entrepreneurship and rapid growth, Technology Fast500 companies are large, small, public and private, and span a variety of industry sectors including hardware, software, telecommunications, media, life sciences and clean technology. For further information on Asia Pacific Technology Fast500, please visit: www.deloitte.com/fast500asiapacific

About GNI Group Ltd.

GNI Group Ltd. is a multinational life science company that focuses on pharmaceutical and medical device businesses. In addition to its CFDA Class 1.1 approved drug Etuary®, the only approved therapy for Idiopathic Pulmonary Fibrosis in China, GNI Group Ltd. has a robust drug development pipeline focused on innovative therapeutic agents for diseases including radiation pneumonitis, diabetic nephropathy, liver fibrosis (cirrhosis), acute-on-chronic liver failure (ACLF) and acute promyelocytic leukemia (APL). GNI Group Ltd. is listed on the Tokyo Stock Exchange Mothers Market, Code 2160, with headquarters in Tokyo and subsidiaries in Hong Kong, Shanghai, Beijing and the United States. For further information, please visit www.gnipharma.com.

For further inquiries

+81 (03) -6214-3600

Email: infojapan@gnipharma.com

This press release contains "forward-looking" statements, including statements related to our group's plans to pursue development of product candidates and the timing thereof. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "continue," "expected to", "will" and similar expressions are intended to identify these forward-looking statements. There are a number of important factors that could cause our group's results to differ materially from those indicated by these forward-looking statements, including risks associated with the timing and success of clinical trials and the commercialization of product candidates. Our group does not undertake any obligation to update forward-looking statements.